Talecris Tries Merger Route Again; Plans Combination With Spain's Grifols
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal would increase Talecris' plasma-collection capabilities while providing an exit to VC backer Cerberus.
You may also be interested in...
Novartis Trims Its Sails, Divests Blood-Testing Unit To Spain’s Grifols
CEO Joe Jimenez delivers on his strategy to free up resources at Novartis by divesting its non-core blood transfusion diagnostics business for $1.7 billion.
Grifols To Divest Factor VIII Product Koate To Merge With Talecris
Italian company Kedrion will get the Factor VIII product Koate and a fractionation facility in Melville, N.Y., under a consent agreement with the Federal Trade Commission.
Grifols To Divest Factor VIII Product Koate To Merge With Talecris
Italian company Kedrion will get the Factor VIII product Koate and a fractionation facility in Melville, N.Y., under a consent agreement with the Federal Trade Commission.